Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice
- 119 Downloads
To acknowledge the facts of gadoxetate disodium-related events in Japan and to achieve better MR practice by analyzing large cohort data with various MR parameters.
Materials and methods
This prospective multi-institutional study included 1993 patients (1201 men, mean age 66.4 ± 12.8 years), who received dynamic MRI with gadoxetate disodium (gadoxetate group, n = 1646) or extracellular gadolinium-based contrast agents (other-GBCAs group, n = 347) between January and November 2016. Recorded data covered adverse reactions including dyspnea, breath-hold failure during acquisition, respiratory artifacts rated with a four-point scale, and MR parameters. We compared data between the two groups in whole cohort and age-, gender-, and institution-matched subcohort using χ2 test (n = 640). Logistic regression model was used to reveal independent associates of substantial artifacts in arterial phase imaging.
Transient dyspnea rarely occurred in gadoxetate or other-GBCAs group (both < 1%). Gadoxetate group (vs other-GBCAs group) showed higher rates of breath-hold failure (whole cohort, 18.2% vs 7.7%, p < 0.001; subcohort, 17.6% vs 6.3%, p < 0.001) and substantial artifacts in arterial phase (7.2% vs 2.2%, p = 0.001; 7.4% vs 1.7%, p = 0.001). With single arterial phase protocol, substantial artifacts under gadoxetate were independently associated with age (odds ratio [OR] = 1.04, p < 0.001), hearing difficulty (OR = 2.92, p = 0.008), breath-hold practice required (OR = 1.61, p = 0.039), and short acquisition time (OR = 0.43, p = 0.005). Multiple arterial phase acquisition did not reduce the incident rate of substantial artifacts.
Gadoxetate disodium was associated with breath-hold failure and substantial artifacts in arterial phase imaging, but not with dyspnea in Japan. Shorter acquisition time should be used to sustain image quality in gadoxetate disodium-enhanced arterial phase imaging.
• Gadoxetate disodium administration leads to breath-hold failure and substantial imaging artifacts in arterial phase MRI in Japan.
• Contrast agent-induced dyspnea in arterial phase and adverse reactions are rare in Japan, without showing differences between gadoxetate disodium or other extracellular gadolinium-based contrast agents.
• Shorter acquisition time significantly reduces gadoxetate-induced imaging artifacts in the arterial phase.
KeywordsDyspnea Breath-holding Magnetic resonance imaging Gadoxetate disodium
Body mass index
Chronic obstructive pulmonary disease
Gadolinium-based contrast agent
Magnetic resonance imaging
Portal venous phase
Transient severe motion
The authors state that this work has not received any funding.
Compliance with ethical standards
The scientific guarantor of this publication is Utaroh Motosugi, MD PhD.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors has significant statistical expertise.
Written informed consent was not required for this study because of the retrospective study design.
Institutional Review Board approval was obtained.
• performed at one institution
- 20.Kaltenbach B, Bucher AM, Wichmann JL et al (2017) Dynamic liver magnetic resonance imaging in free-breathing: feasibility of a Cartesian T1-weighted acquisition technique with compressed sensing and additional self-navigation signal for hard-gated and motion-resolved reconstruction. Invest Radiol 52:708–714CrossRefGoogle Scholar